Form 8-K - Current report:
SEC Accession No. 0001493152-24-026467
Filing Date
2024-07-08
Accepted
2024-07-08 16:01:32
Documents
19
Period of Report
2024-07-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 50557
2 ex10-1.htm EX-10.1 157921
3 ex10-2.htm EX-10.2 91425
4 ex10-1_001.jpg GRAPHIC 13399
5 ex10-1_002.jpg GRAPHIC 6111
6 ex10-2_001.jpg GRAPHIC 13399
7 ex10-2_002.jpg GRAPHIC 6111
  Complete submission text file 0001493152-24-026467.txt   556885

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE rspi-20240702.xsd EX-101.SCH 3018
9 XBRL LABEL FILE rspi-20240702_lab.xml EX-101.LAB 34240
10 XBRL PRESENTATION FILE rspi-20240702_pre.xml EX-101.PRE 22361
21 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3400
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

EIN.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16467 | Film No.: 241104664
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)